Zoghbi Y. Huda's most recent trade in Regeneron Pharmaceuticals, Inc. was a trade of 1,958 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharma | Huda Y. Zoghbi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,958 | 1,958 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 166 | 1,548 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,607 | 1,607 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 391.92 per share. | 02 Jan 2024 | 1,117 | 2,364 (0%) | 0% | 391.9 | 437,775 | Common Stock |
| Regeneron Pharma | Y. Huda Zoghbi | Director | Sale of securities on an exchange or to another person at price $ 900.00 per share. | 02 Jan 2024 | 1,117 | 1,247 (0%) | 0% | 900 | 1,005,300 | Common Stock |
| Regeneron Pharma | Zoghbi Huda Y. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 1,117 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Zoghbi Y. Huda | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 135 | 1,382 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 1,929 | 1,929 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 165 | 1,247 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 391.92 per share. | 16 Mar 2022 | 2,000 | 3,082 (0%) | 0% | 391.9 | 783,840 | Common Stock |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Sale of securities on an exchange or to another person at price $ 675.00 per share. | 16 Mar 2022 | 2,000 | 1,082 (0%) | 0% | 675 | 1,350,000 | Common Stock |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2022 | 2,000 | 2,117 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 2,707 | 2,707 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 191 | 1,082 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 391.92 per share. | 13 Sep 2021 | 998 | 1,889 (0%) | 0% | 391.9 | 391,136 | Common Stock |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Sale of securities on an exchange or to another person at price $ 650.00 per share. | 13 Sep 2021 | 998 | 891 (0%) | 0% | 650 | 648,700 | Common Stock |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 998 | 4,117 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 392.00 per share. | 13 Sep 2021 | 2 | 893 (0%) | 0% | 392 | 784 | Common Stock |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Sale of securities on an exchange or to another person at price $ 651.00 per share. | 13 Sep 2021 | 2 | 891 (0%) | 0% | 651 | 1,302 | Common Stock |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 2 | 5,115 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 3,613 | 3,613 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Huda Y. Zoghbi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 248 | 891 (0%) | 0% | 0 | Common Stock |